Trichostatin A, an HDAC class I/II inhibitor, promotes Pi-induced vascular calcification via up-regulation of the expression of alkaline phosphatase

Journal of Atherosclerosis and Thrombosis

Volumn 20, Issue 6, 2013, Pages 538-547

  Azechi, Takuya ^a   Kanehira, Dan ^a   Kobayashi, Takashi ^a   Sudo, Ryo ^a   Nishimura, Akiko ^a   Sato, Fumiaki ^a   Wachi, Hiroshi ^a  

^a HOSHI UNIVERSITY   (Japan)

Author keywords

Alkaline phosphatase; Inorganic phosphorus; Trichostatin A; Vascular calcification; Vascular smooth muscle cells

Indexed keywords

ALKALINE PHOSPHATASE; FOSCARNET; HISTONE DEACETYLASE; PHOSPHATE; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR PIT 1; TRANSCRIPTION FACTOR RUNX; TRICHOSTATIN A;

AORTA MEDIA; APOPTOSIS; ARTICLE; BLOOD VESSEL CALCIFICATION; CALCIUM BLOOD LEVEL; CELL DIFFERENTIATION; CELL VIABILITY; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; ENZYME INDUCTION; GENE EXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; OSTEOBLAST; PHOSPHATE BLOOD LEVEL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SMOOTH MUSCLE FIBER; STAINING; TISSUE DIFFERENTIATION; WESTERN BLOTTING;

ALKALINE PHOSPHATASE; CALCINOSIS; CELL SURVIVAL; CELLS, CULTURED; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; MYOCYTES, SMOOTH MUSCLE; PHOSPHATES; RNA, SMALL INTERFERING; UP-REGULATION;

EID: 84879518259     PISSN: 13403478     EISSN: 18803873     Source Type: Journal    
DOI: 10.5551/jat.15826     Document Type: Article

References (51)

1. Keith DS, Nichols GA, Gullion CM, Brown JB, Smith DH: Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern Med, 2004; 164: 659-663
2. Kannel WB, Stampfer MJ, Castelli WP, Verter J: The prognostic significance of proteinuria: the Framingham study. Am Heart J, 1984; 108: 1347-1352
3. Ninomiya T, Kiyohara Y, Kubo M, Tanizaki Y, Doi Y, Okubo K, Wakugawa Y, Hata J, Oishi Y, Shikata K, Yonemoto K Hirataka H, Iida M: Chronic kidney disease and cardiovascular disease in a general Japanese population: the Hisayama study. Kidney Int, 2005; 68: 228-236
4. Foley RN, Parfrey PS, Sarnak MJ: Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis, 1998; 32: S112-119
5. London GM, Guérin AP, Marchais SJ, Métivier F, Pannier B, Adda H: Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant, 2003; 18: 1731-1740
6. Sigrist M, Bungay P, Taal MW, Mclntyre CW: Vascular calcification and cardiovascular function in chronic kidney disease. Nephrol Dial Transplant, 2006; 21: 707-714
7. Goodman WG, Goldin J, Kuizon BD, Yoon C, Gales B, Sider D, Wang Y, Chung J, Emerick A, Greaser L, Elashoff RM, Salusky IB: Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med, 2000; 342: 1478-1483
8. Kestenbaum B, Sampson JN, Rudser KD, Patterson DJ, Seliger SL, Young B, Sherrard DJ, Andress DL: Serum phosphate levels and mortality risk among people with chronic kidney disease. J Am Soc Nephrol, 2005; 16: 520-528
9. Cannata-Andie JB, Rodriguez-Garcia M, Carrillo-López N, Naves-Diaz M, Diaza-López B: Vascular calcification: pathogenesis, management and impact on clinical outcome. J Am Soc Nephrol, 2006; 17: S267-S273
10. Pecovnik-Balon B: Cardiovascular calcification in patients with end-stage renal disease. Ther Apher Dial, 2005; 9: 208-210
11. Moe SM, Chen NX: Mechanisms of vascular calcification in chronic kidney disease. J Am Soc Nephrol, 2008; 19: 213-216
12. Shanahan CM, Crouthamel MH, Kapustin A, Giachelli CM: Arterial calcification in chronic kidney disease: key roles for calcium and phosphate. Circ Res, 2011; 109: 697-711
13. Lee HL, Woo KM, Ryoo HM, Baek JH: Tumor necrosis factor-α increases alkaline phosphatase expression in vascular smooth muscle cells via MSX2 induction. Biochem Biophys Res Commun, 2010; 391: 1087-1092
14. Tintut Y, Patel J, Parhami F, Demer LL: Tumor necrosis factor-alpha promotes in vitro calcification of vascular cells via the cAMP pathway. Circulation, 2000; 102: 2636-2642
15. Sun G, Fu C, Shen C, Shi Y: Histone deacetylases in neu ral stem cells and induced pluripotent stem cells. J Biomed Biothechnol, 2011; 2011: 835-968
16. Hagelkruys A, Sawicka A, Rennmayr M, Seiser C; The biology of HDAC in cancer: the nuclear and epigenetic components. Handb Exp Pharmacol, 2011; 206: 13-37
17. Sweet MJ,Shakespear MR,Kamal NA,Fairlie DP: HDAC inhibitors: Modulating leukocyte differentiation, survival, proliferation and inflammation. Immunol Cell Biol, 2012; 90: 14-22
18. Gray SG, Ekstrom TJ: Histone acetylation/deacetylation and cancer: an "open" and "shut" case?Curr Mol Med, 2001; 1: 401-429
19. Rosato RR, Grant S: Histone deacetylase inhibitors in cancer therapy. Cancer Biol Ther, 2003; 2: 30-37
20. Pons D, de Vries FR, van den Elsen PJ, Heijmans BT, Quax PH, Jukema JW: Epigenetic histone acetylation modifiers in vascular remodeling: new targets for therapy in cardiovascular disease. Eur Heart J, 2009; 30: 266-277
21. Westendorf J: Histone deacetylases in control of skeletogenesis. J Cell Biochem, 2007; 102: 332-340
22. Lee HW, Suh JH, Kim AY, Lee YS, Park SY, Kim JB: His tone deacetylase 1-mediated histone modification regulates osteoblast differentiation. Mol Endocrinol, 2006; 20: 2432-2443
23. Jensen ED, Schroeder TM, Bailey J, Gopalakrishnan R, Westendorf J: Histone deacetylase 7 associates with runx2 and represses its activity during osteoblast maturation in deacetylation-independent manner. J Bone Miner Res, 2008; 23: 361-372
24. Schroeder TM, Westendorf JJ: Histone deacetylase inhibi tors promote osteoblast maturation. J Bone Miner Res, 2005; 20: 2254-2263
25. Chen TH, Chen WM, Hsu KH, Kuo CD, Hung SC: Sodium butyrate activates ERK to regulate differentiation of mesenchymal stem cells. Biochem Biophys Res Commun, 2007; 355: 913-918
26. Schoppet M, Al-Fakhri N, Franke FE, Katz N, Barth PJ, Maisch B, Preissner KT, Hofbauer LC: Localization of osteoprotegerin, tumor necrosis factor-related apoptosisinducing ligand, and receptor activator of nuclear factorkappaB ligand in Mönckeberg's sclerosis and atherosclerosis. J Clin Endocrinol Metab. 2004; 89: 4104-4112
27. Son BK, Akishita M, Iijima K, Eto M, Ouchi Y: Mechanism of pi-induced vascular calcification. J Atheroscler Thromb. 2008; 16: 63-68
28. Murshed M, Harmey D, Millan JL, McKee MD, Karsenty G: Unique coexpression in osteoblasts of broadly expressed genes accounts for the spatial restriction of ECM mineralization to bone. Genes Dev, 2005; 19: 1093-1104
29. Harada H, Tagashira S, Fujiwara M, Ogawa S, Katsumata T, Yamaguchi A, Komori T, Nakatsuka M: Cbfa1 isoforms exert functional differences in osteoblast differentiation. J Biol Chem, 1999; 274: 6972-6978
30. Jun JH, Yoon WJ, Seo SB, Woo KM, Kim GS, Ryo HM, Baek JH: BMP2-activated Erk/MAP kinase stabilizes Runx2 by increasing p300 levels and histone acetyltransferase activity. J Biol Chem, 2010; 285: 36410-36419
31. Schlottmann S, Erkizan HV, Barber-Rotenberg JS, Knights C, Cheema A, Uren A, Avantaggiati ML, Toretsky JA: Acetylation increases EWS-FLI1 DNA binding and transcriptional activity. Front Oncol, 2012; 2: 107
32. Wang W, Pan K, Chen Y, Huang C, Zhang X: The acety lation of transcription factor HBP1 by p300/CBP enhances p16INK4A expression. Nucleic Acid Res, 2012; 40: 981995
33. Kim JH, Kim K, Youn BU, Jin HM, Kim JY, Moon JB, Ko A, Seo SB, Lee KY, Kim N: RANKL induces NFATc1 acetylation and stability via histone acetyltransferase during osteoclast differentiation. Biochem J, 2011; 436: 253-262
34. Jeon EJ, Lee KY, Choi NS, Lee MH, Kim HN, Jin YH, Ryoo HM, Choi JY, Yoshida M, Nishino N, Oh BC, Lee KS, Lee YH, Bae SC: Bone morphogenetic protein-2 stimulates Runx2 acetylation. J Biol Chem, 2006; 281: 16502-16511
35. Hui M, Li SQ, Holmyard D, Cheng P: Stable transfec tion of nonosteogenic cell line with ALP enhances mineral deposition in the presence and absence of β-glyserophosphate: possible role for alkaline phosphatase in pathological mineralization. Calcif Tissue Int, 1997; 60: 467-472
36. Narisawa S, Harmey D, Yadav MC, O'Neill WC, Hoylaerts MF, Millán JL: Novel inhibitors of alkaline phosphatase suppression vascular smooth muscle cell calcification. J Bone Miner Res, 2007; 22: 1700-1710
37. Lau WL, Festing MH, Giachelli CM: Phosphate and vas cular calcification: Emerging role of the sodium-dependent phosphate co-transporter PiT-1. Thromb Haemost, 2010; 104: 464-470
38. Li X, Yang HY, Giachelli CM: Role of the sodium-depen dent phosphate cotransporter, Pit-1, in vascular smooth muscle cell calcification. Circ Res, 2006; 98: 905-912
39. Mune S, Shibata M, Hatamura I, Saji F, Okada T, Maeda Y, Sakaguchi T, Negi S, Shigematsu T: Mechanism of phosphate-induced calcification in rat aortic tissue culture: possible involvement of Pit-1 and apoptosis. Clin Exp Nephrol, 2009; 13: 571-577
40. Takemura A, Iijima K, Ota H, Son BK, Ito Y, Ogawa S, Eto M, Akishita M, Ouchi Y: Sirtuin 1 retards hyperphosphatemia-induced calcification of vascular smooth muscle cells. Arterioscler Thromb Vasc Biol, 2011; 31: 2054-2062
41. Nath KA: The tubulointerstitium in progressive renal disease. Kindey Int, 1998; 54: 992-994
42. Jones PA, Baylin SB: The fundamental role of epigenetic events in cancer. Nat Rev Genet, 2002; 3: 415-428
43. Issa JP, Garcia-Manero G, Giles FJ, Mannari R, Thomas D, Faderl S, Bayar E, Lyons J, Rosenfeld CS, Cortes J, Kantarjian HM: Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza2'-deoxycytidine (decitabine) in hematopoietic malignancies. Blood, 2004; 103: 1635-1640
44. Kan PX, Popendikyte V, Kaminsky ZA, Yolken RH, Petro nis A: Epigenetic studies of genomic retroelements in major psychosis. Schizophr Res, 2004; 67: 95-106
45. Kato C, Petronis A, Okazaki Y, Tochigi M, Umekage T, Sasaki T: Molecular genetic studies of schizophrenia: challenges and insights. Neurosci Res, 2002; 43: 295-304
46. Marumoto T, Hishikawa K, Yoshikawa M, Hirahashi J, Kawachi S, Fujita T: Histone deacetylase modulates the proinflammatory and fibrotic changes in tubulointerstitial injury. Am J Physiol Renal Physiol, 2010; 298: F133-F141
47. Pang M, Zhuang S: Histone deacetylase: a potential therapeutic target for fibrotic disorders. J Pharmacol Exp Ther, 2010; 335: 266-272
48. Kinugasa F, Noto T, Matsuoka H, Urano Y, Sudo Y, Takakkura S, Mutoh S: Prevention of renal interstitial fibrosis via histone deacetylase inhibition in rats with unilateral ureteral obstruction. Transpl Immunol, 2010; 23: 18-23
49. Choi JH, Nam KH, Kim J, Baek MW, Park JE, Park HY, Kwon HJ, Kwon OS, Kim DY, Oh GT: Trichostatin A exacerbates atherosclerosis in low density lipoprotein receptor-deficient mice. Arterioscler Thromb Vasc Biol, 2005; 25: 2404-2409
50. Westerberg PA, Linde T, Wikström B, Ljunggren O, Strids berg M, Larsson TE: Regulation of fibroblast growth factor-23 in chronic kidney disease. Nephrol Dial Transplant, 2007; 22: 3202-3207
51. Ambrus C, Molnar MZ, Czira ME, Rosivall L, Kiss I, Remport A, Szathmari M, Mucsi I: Calcium, phosphate and parathyroid metabolism in kidney transplanted patients. Int Urol Nephrol, 2009; 41: 1029-1038